Teva and Servier spring to the aid of Russia with cancer drugs

23 March 2021

Russia may face a shortage of some anti-cancer drugs for children, which is mainly due to the suspension of their supplies to the local market by local producers and importers, reports The Pharma Letter’s local correspondent.

One of such drugs is vero-vincristine, a drug, which is used to treat blood cancer in children and is produced by Veropharm, part of the USA’s Abbott (NYSE: ABT). In recent months, the company has almost completely suspended its supplies to the domestic market.

As some Russian media reported, citing the company, the main reason for interruption of supplies is the change in production technology.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK